EGFR and lung cancer: Cisplatin (cis-diamminedichloroplatinum (II); DDP), a commonly used platinum-based chemotherapy drug for the treatment of lung cancer, induces cell death via caspase-dependent or independent pathways regardless of the EGFR genotype7.